



Patient ID SA00161857	Patient Name SAMPLE REPORT, MOG1	Birth Date 2003-08-21	Sex F	Age 19
Order Number SA00161857	Client Order Number SA00161857	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 20 Aug 2023 01:22		

CNS Demyelinating Disease Eval, S

CNS Demyelinating Disease Interp, S

MCR

The following antibodies were identified: MOG IgG.

- Clear positive MOG-IgG detection with an end titer $\geq 1:1000$ have a positive predictive value of approximately 100% for MOG antibody associated disorder (MOGAD).
- MOGAD is a monophasic or relapsing CNS demyelinating disease that may affect any age with children particularly predisposed. Clinical manifestations include optic neuritis, transverse myelitis, acute disseminated encephalomyelitis (ADEM), neuromyelitis optica or unilateral cortical encephalitis. A progressive course does not occur, CSF oligoclonal bands are rare ($<15\%$) and MOGAD MRI lesions often differ in morphology and evolution from MS. Repeat MOG-IgG testing 6–12 months after disease onset may assist prognosis as persistence increases the risk of relapsing disease over a monophasic disorder.
- Reference: Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenenbaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J. Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: International MOGAD Panel Proposed Criteria. Lancet Neurol. 2023 Mar; 22(3): 268–282. Sechi E, Buciuc M, Pittock SJ, et al. Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA Neurol. 2021;78(6):741–746.

Result Name	Result	Unit	Reference Value	Performing Site
 Abn MOG FACS, S	Reactive		Negative	1 MCR
Screen Reactive, see confirmatory test results.				
NMO/AQP4 FACS, S	Negative		Negative	1 MCR

Received: 21 Aug 2023 13:42

Reported: 21 Aug 2023 13:55

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292

Patient ID SA00161857	Patient Name SAMPLE REPORT, MOG1	Birth Date 2003-08-21	Sex F	Age 19
Order Number SA00161857	Client Order Number SA00161857	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 20 Aug 2023 01:22		

MOG FACS Titer, S

Result Name	Result	Unit	Reference Value	Performing Site
 MOG FACS Titer, S 	Positive 1:1000	titer	<1:20	1 MCR

MOG-IgG detection with an end titer of $\geq 1:1000$ is considered clear positive by the 2023 MOG antibody-associated disease (MOGAD) diagnostic criteria and has a positive predictive value of approximately 100% for MOGAD.

- MOGAD is a monophasic or relapsing CNS demyelinating disease that may affect any age with children particularly predisposed. Clinical manifestations include optic neuritis, transverse myelitis, acute disseminated encephalomyelitis (ADEM), neuromyelitis optica or unilateral cortical encephalitis. A progressive course does not occur, CSF oligoclonal bands are rare (<15%) and MOGAD MRI lesions often differ in morphology and evolution from MS. Repeat MOG-IgG testing 6–12 months after disease onset may assist prognosis as persistence increases the risk of relapsing disease over a monophasic disorder.
- References: Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J. Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: International MOGAD Panel Proposed Criteria. *Lancet Neurol.* 2023 Mar; 22(3): 268–282. Sechi E, Buciuc M, Pittock SJ, Chen JJ, Fryer JP, Jenkins SM, Budhram A, Weinshenker BG, Lopez-Chiriboga AS, Tillema JM, McKeon A, Mills JR, Tobin WO, Flanagan EP. Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. *JAMA Neurol.* 2021 Jun 1; 78(6): 741–74.

Received: 21 Aug 2023 13:42

Reported: 21 Aug 2023 13:54

Laboratory Notes

- 1** This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292